Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Gansu Fuzheng Pharmaceutical Technology
Dingxi, Gansu Sheng, Chinafuzhengyaoye.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Gansu Fuzheng Pharmaceutical Technology is conducting a Phase 2 randomized, double-blind, multicenter clinical trial evaluating the safety and efficacy of Zhenqi Fuzheng Capsule in combination with surgery, chemotherapy, and radiotherapy for non-small cell lung cancer and nasopharyngeal carcinoma. The company focuses on improving quality of life for patients with Qi-Yin deficiency syndromes post-cancer treatment. No published results from completed trials are available as of May 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeHerbal medicine
- Industry
- Biotech
02
Partnerships
No major international pharmaceutical or biotech partnerships publicly disclosed.
Beyond the preview
Go deeper on Gansu Fuzheng Pharmaceutical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gansu Fuzheng Pharmaceutical Technology.